Table 2 ALK inhibitors in development
From: Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
Chemical series | Therapeutics | Development stage |
|---|---|---|
Aminopyridine | PF-2341066 (crizotinib) | Phase II/III: NSCLC; phase I/II: advanced solid tumors, neuroblastoma, and ALCL |
Diaminopyrimidine | CEP-28122 | Preclinical IND application expected |
Structure undisclosed | AP-26113 | Preclinical IND application expected in 2011 |
Structure undisclosed | X-276 | Preclinical |
Pyridoisoquinoline | F91873 and F91874 | Preclinical |
Pyrrolopyrazole | PHA-E429 | Preclinical |
Indolocarbazole | CEP-14083 and CEP-14513 | Preclinical No further development |
Pyrrolopyrimidine | GSK1838705A | Preclinical No further development |
Dianilinopyrimidine | NVP-TAE684 | Preclinical No further development |